Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies
Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies - Registry
Centre hospitalier de l'Université de Montréal (CHUM)
3,600 participants
Sep 13, 2019
OBSERVATIONAL
Conditions
Summary
Every year, new molecular agents enter the market with more and more patients receiving these treatments, especially in the metastatic setting. These molecular agents could correspond to immunotherapy and modulators of signaling pathways. More than 50% of cancer patients will receive radiation therapy during the course of their illness, including radiotherapy aimed a palliating symptoms secondary to metastatic diseases. Therefore, there will be an increasing number of patients who will be receiving radiotherapy while they are still receiving molecular agents. A better understanding of the interaction of these two treatment modalities is needed.
Eligibility
Inclusion Criteria7
- Consent to be part of the AtTRIBut registry
- Prior histological diagnosis of primary cancer.
- If the patient has metastatic disease, there must be radiological or pathological evidence of metastasis
- Age> 18 years
- Receiving a molecular therapy
- Indicated to receive radiotherapy
- Radiation therapy can be administered using 3D conventional, IMRT or SBRT techniques.
Exclusion Criteria1
- Refusal or inability to receive radiotherapy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Combined modality
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04115267